Telix Pharmaceuticals Ltd. (TLX) saw its stock surge 10% in after-hours trading on Tuesday, following the announcement that a research center in Miami has begun recruiting and dosing patients for the company's Phase 3 clinical trial of TLX591, an investigational treatment for advanced prostate cancer.
The ProstACT Global Phase 3 trial is evaluating TLX591, a radioantibody-drug conjugate (rADC) that targets prostate-specific membrane antigen (PSMA), in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to assess the safety and efficacy of TLX591 as a first-line or second-line treatment option for this patient population.
The Biogenix Molecular Research Center in Miami has successfully administered the first two doses of TLX591 to a local patient and continues to recruit eligible participants for the trial. According to the center's director, Dr. Frankis Almaguel, there is a significant unmet need for effective combination therapies in mCRPC, and TLX591 has shown promising results in earlier-stage trials.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。